ETTX Entasis Therapeutics Holdings Inc. Stock Quote

ETTX [NASD]

Index	-	P/E	-	EPS (ttm)	-3.36	Insider Own	52.60%	Shs Outstand	29.96M	Perf Week	31.91%
Market Cap	105.46M	Forward P/E	-	EPS next Y	-1.23	Insider Trans	35.34%	Shs Float	13.57M	Perf Month	29.71%
Income	-53.80M	PEG	-	EPS next Q	-0.39	Inst Own	31.00%	Short Float	0.60%	Perf Quarter	44.86%
Sales	0.00M	P/S	-	EPS this Y	-3.50%	Inst Trans	-	Short Ratio	0.11	Perf Half Y	-4.62%
Book/sh	2.08	P/B	1.49	EPS next Y	49.00%	ROA	-101.50%	Target Price	-	Perf Year	-36.85%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-118.70%	52W Range	1.58 - 5.64	Perf YTD	25.51%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-112.80%	52W High	-45.04%	Beta	-
Dividend %	-	Quick Ratio	10.00	Sales past 5Y	-	Gross Margin	-	52W Low	96.20%	ATR	0.23
Employees	47	Current Ratio	10.00	Sales Q/Q	-	Oper. Margin	-	RSI (14)	71.49	Volatility	9.64% 9.12%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-40.00%	Profit Margin	-	Rel Volume	0.52	Prev Close	3.01
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	736.49K	Price	3.10
Recom	1.90	SMA20	20.62%	SMA50	44.82%	SMA200	22.91%	Volume	391,179	Change	2.99%

Sep-09-20

Initiated

Cantor Fitzgerald

Overweight

Jul-13-20

Initiated

ROTH Capital

Buy

Jan-07-21 08:00AM	Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference GlobeNewswire +5.28%
Dec-01-20 01:52AM	We Think Entasis Therapeutics Holdings (NASDAQ:ETTX) Needs To Drive Business Growth Carefully Simply Wall St.
Nov-17-20 08:00AM	Entasis Therapeutics to Participate in A.G.P.s Virtual Healthcare Symposium GlobeNewswire
Nov-05-20 04:05PM	Entasis Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Business Update GlobeNewswire
Oct-14-20 08:00AM	Entasis Therapeutics Highlights Multiple Data Presentations at Virtual ID Week GlobeNewswire
Oct-08-20 08:32AM	New Strong Sell Stocks for October 8th Zacks
Sep-10-20 08:00AM	Entasis Therapeutics to Participate in Upcoming Healthcare Investor Conferences GlobeNewswire
Aug-28-20 08:00AM	Entasis Therapeutics Announces $25 Million Private Placement GlobeNewswire
Aug-06-20 04:05PM	Entasis Therapeutics Reports Second Quarter 2020 Financial Results and Business Update GlobeNewswire
Aug-05-20 08:00AM	Entasis Therapeutics to Participate in Upcoming Healthcare Conferences GlobeNewswire
Jul-13-20 10:05AM	Entasis Therapeutics (ETTX) Jumps: Stock Rises 5.4% Zacks
Jul-06-20 08:00AM	Entasis Therapeutics Awarded Contract from National Institutes of Health GlobeNewswire
Jun-22-20 09:48AM	Analysts: These 3 Penny Stocks May Very Well Be Worth the Risk TipRanks
Jun-18-20 08:00AM	Entasis Therapeutics to Participate in the BMO 2020 Prescriptions for Success Healthcare Conference GlobeNewswire
Jun-11-20 04:05PM	Entasis Therapeutics Completes Closing of Second Tranche of $35M Private Placement with Innoviva GlobeNewswire -9.06%
May-18-20 11:34AM	Analysts Suggest Buying These 2 Falling Knives GuruFocus.com +9.76%
May-07-20 04:05PM	Entasis Therapeutics Reports First Quarter 2020 Financial Results and Business Update GlobeNewswire
Apr-22-20 04:05PM	Entasis Therapeutics Completes Initial Closing of $35M Private Placement with Innoviva GlobeNewswire
Mar-13-20 07:46AM	Earnings Release: Here's Why Analysts Cut Their Entasis Therapeutics Holdings Inc. Price Target To US$14.50 Simply Wall St. -12.20%
Mar-11-20 04:05PM	Entasis Therapeutics Reports Full Year 2019 Financial Results and Business Update GlobeNewswire
Dec-19-19 09:49AM	Introducing Entasis Therapeutics Holdings (NASDAQ:ETTX), The Stock That Dropped 16% In The Last Year Simply Wall St.
Nov-24-19 01:56PM	Entasis Therapeutics Holdings Inc. (ETTX): Are Hedge Funds Right About This Stock? Insider Monkey
Nov-14-19 07:30AM	Entasis Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Oct-30-19 04:05PM	Entasis Therapeutics Appoints Dr. David Altarac as Chief Medical Officer GlobeNewswire
Oct-29-19 08:30AM	Entasis Therapeutics to Present at the 28th Annual Credit Suisse Healthcare Conference GlobeNewswire
Oct-03-19 04:01PM	Entasis Therapeutics Announces Multiple Presentations at ID Week 2019 Globenewswire Test +8.05%
04:01PM	Entasis Therapeutics Announces Multiple Presentations at ID Week 2019 GlobeNewswire
Oct-01-19 10:07AM	Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019 PR Newswire -5.37%
Sep-30-19 01:00AM	GARDP and Entasis Therapeutics Initiate Global Phase 3 Trial of Zoliflodacin, a First-in-Class Oral Antibiotic for the Treatment of Gonorrhea GlobeNewswire
Sep-19-19 11:56AM	Should You Sell Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) For This Reason? Simply Wall St.
Sep-03-19 08:00AM	Entasis Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference GlobeNewswire -8.78%
Aug-12-19 07:30AM	Entasis Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Aug-06-19 08:00AM	Entasis Therapeutics to Present at the Wedbush PacGrow Healthcare Conference GlobeNewswire
Jul-01-19 09:13AM	X-Biotix Therapeutics Joins Antimicrobials Working Group PR Newswire
Jun-27-19 08:00AM	Entasis Therapeutics Announces New Results Supporting Advancement of Multiple Pathogen-Targeted Antimicrobial Programs at ASM Microbe 2019 GlobeNewswire +5.64%
Jun-24-19 08:00AM	Entasis Therapeutics Appoints David Meek as Chairman of the Board GlobeNewswire
Jun-20-19 11:13AM	Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019 PR Newswire
Jun-18-19 04:01PM	Entasis Therapeutics to Participate in the BMO 2019 Prescriptions for Success Healthcare Conference GlobeNewswire
Jun-13-19 08:00AM	Entasis Therapeutics Announces Initial ETX0282 Phase 1 Results GlobeNewswire
Jun-10-19 08:00AM	Entasis Therapeutics Announces Oral and Poster Presentations of its Pathogen-Targeted Antibiotic Clinical Programs at ASM Microbe 2019 GlobeNewswire +5.52%

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. It is involved in developing Sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that has completed Phase II clinical trial for the treatment of multi-drug resistant Acinetobacter infections; Zoliflodacin, a novel orally administered molecule that has completed Phase II clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant Gram-negative infections. The company has collaboration agreements with Zai Lab (Shanghai) Co., Ltd. for developing SUL-DUR. Entasis Therapeutics Holdings Inc. was incorporated in 2018 and is based in Waltham, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Innoviva, Inc.	10% Owner	Sep 01	Buy	2.68	4,672,897	12,499,999	18,672,897	Sep 01 05:31 PM
Innoviva, Inc.	10% Owner	Jun 11	Buy	2.50	12,677,490	31,693,725	14,000,000	Jun 12 05:34 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience